



106° CONGRESSO NAZIONALE
SOCIETÀ ITALIANA DI FISICA
14-18 settembre 2020

Towards a Standard Pipeline for the Analysis of Human Spinal Cord fMRI Data

Marta Moraschi^a, Mauro DiNuzzo^b, Laura Maugeri^{b,c}, Fabio Mangini^b, Daniele Mascali^a,
Federico Giove,^{a,b} , Michela Fratini^{b,c}

^a*Museo Storico della Fisica e Centro Studi e Ricerche Enrico Fermi, Rome, 00184, Italy*

^b*Fondazione Santa Lucia IRCCS, Rome, 00179, Italy*

^c*CNR-NANOTEC , Rome 00185, Italy*




SCIENTIFIC PROBLEM

fMRI techniques based on the BOLD signal have already been exploited for the indirect study of the neuronal activity both in the brain and in the spinal cord

BUT

limited use in the study of the **spinal cord function** because of:


1. obtaining good functional images of the SC still represents a technical and scientific challenge
2. the exact features –and even the biophysical origins– of the functional response in the SC are still unclear.



If these challenges can be overcome, **ScfMRI** may be of immediate application for the assessment and follow-up of spinal injuries, pain, and neurodegenerative diseases.



MULTIMODAL APPROACH




Spinal fMRI
Isometric motor task




MATERIALS AND METHODS


We acquired axial and sagittal functional images at 3T from the spinal cord of 46 healthy subjects (all right-handed with a mean age of 35 years) while performing a block-design isometric motor task consisting of 5 cycles of 30s/30s rest/task epochs.

Technical conditions to provide the best NMR-image quality

| | |
|--------------------|---|
| GE-EPI |  |
| TE/TR | 25/3000 ms |
| Flip angle | 80° |
| Acquisition matrix | |
| (sagittal) | 128x128x35 |
| (axial) | 96x96x34 |
| Resolution | |
| (sagittal) | 3x1.5x2 mm |
| (axial) | 1.5x1.5x3 mm |
| FO V | |
| (sagittal) | 192x144x104 mm |
| (axial) | 140x140x143 mm |
| T1-weighted GE | |
| TE/TR | 5.89/9.59 ms |
| flip angle | 9° |
| FOV | 240x240x192 cm |
| Resolution | 0.75x0.75x1.5mm |



METHODS: SCfMRI DATA ANALYSIS PIPELINE



RESULTS RELATIVES TO :


OPTIMIZED
SCfMRI EXPERIMENTAL
& DATA ANALYSIS PROTOCOL




tSNR

25

0



Mean tSNR Map for Ax




Mean tSNR Map for Sag




TSNR

Ax Red – Sag Blu

SD




SEM



| LEVELS | t | p | N | Power of test with alfa | Normality test |
|--------|--------|---------|----|-------------------------|----------------|
| 1 | -1.956 | 0.0638 | 22 | 0.050: 0.463 | passed |
| 2 | 1.639 | 0.110 | 38 | 0.050: 0.358 | passed |
| 3 | 0.0965 | 0.924 | 45 | 0.050: 0.051 | passed |
| 4 | 2.385 | 0.021* | 45 | 0.050: 0.645 | passed |
| 5 | 6.037 | <0.001* | 45 | 0.050: 1.000 | passed |
| 6 | 5.644 | <0.001* | 45 | 0.050: 1.000 | failed |
| 7 | 5.446 | <0.001* | 45 | 0.050: 1.000 | passed |
| 8 | 3.558 | <0.001* | 45 | 0.050: 0.936 | passed |
| 9 | 2.044 | 0.0471* | 44 | 0.050: 0.515 | passed |



RESULTS: SCT fMRI MOCO vs AFNI 3dWarpDrive



Representative tSNR maps from a healthy subject before and after SCT fMRI MoCo (left)




CV's for AFNI 3dWarpDrive and SCT fMRI MoCo were :

59% and 44% for sagittal images, respectively

43% and 36% for axial images, respectively.

The increase in tSNR is statistically significant.

* $p < 0.05$, *** $p < 0.001$.



Group statistics for tSNR after motion correction performed either with AFNI or SCT (right).

CONCLUSIONS

- We implemented and optimized a scfMRI data analysis pipeline built around the Spinal Cord Toolbox (SCT). We acquired axial and sagittal functional images at 3T from the spinal cord of forty-six healthy subjects performing an isometric motor task.
- Using our SCTbased pipeline with an ad hoc experimental setting, we substantially improved motion correction and image registration.
- This result is of great importance for the SC-fMRI application in neuroradiology, and in particular for the assessment and follow-up of spinal injuries, pain, and neurodegenerative diseases (e.g multiple sclerosis), as well as in the development and evaluation of new therapies.

ACKNOWLEDGEMENTs

TecnoMed*Puglia*

